198 related articles for article (PubMed ID: 18254488)
1. Usefulness of skin testing with platinum salts to demonstrate lack of cross-reactivity between carboplatin and cisplatin.
Enrique E; Malek T; Castelló JV; de Mateo JA
Ann Allergy Asthma Immunol; 2008 Jan; 100(1):86. PubMed ID: 18254488
[No Abstract] [Full Text] [Related]
2. Diagnostic and predictive value of skin testing in platinum salt hypersensitivity.
Leguy-Seguin V; Jolimoy G; Coudert B; Pernot C; Dalac S; Vabres P; Collet E
J Allergy Clin Immunol; 2007 Mar; 119(3):726-30. PubMed ID: 17258305
[TBL] [Abstract][Full Text] [Related]
3. Administration of cisplatin in three patients with carboplatin hypersensitivity: is skin testing useful?
Syrigou E; Makrilia N; Vassias A; Nikolaidis I; Xyla V; Manolopoulos L; Syrigos K
Anticancer Drugs; 2010 Mar; 21(3):333-8. PubMed ID: 20038831
[TBL] [Abstract][Full Text] [Related]
4. Safety of cisplatin after severe hypersensitivity reactions to carboplatin in patients with recurrent ovarian carcinoma.
Ottaiano A; Tambaro R; Greggi S; Prato R; Di Maio M; Esposito G; Scala F; Barletta E; Losito S; De Vivo R; Iaffaioli VR; Pignata S
Anticancer Res; 2003; 23(4):3465-8. PubMed ID: 12926091
[TBL] [Abstract][Full Text] [Related]
5. Hypersensitivity reactions and the utility of oral and intravenous desensitization in patients with gynecologic malignancies.
Robinson JB; Singh D; Bodurka-Bevers DC; Wharton JT; Gershenson DM; Wolf JK
Gynecol Oncol; 2001 Sep; 82(3):550-8. PubMed ID: 11520154
[TBL] [Abstract][Full Text] [Related]
6. Anaphylaxis to carboplatin following multiple previous uncomplicated courses.
Sood AK; Gelder MS; Huang SW; Morgan LS
Gynecol Oncol; 1995 Apr; 57(1):131-2. PubMed ID: 7705695
[TBL] [Abstract][Full Text] [Related]
7. [Tolerance induction in anaphylaxis to carboplatin].
Herzinger T; Behr J; Przybilla B
Dtsch Med Wochenschr; 2003 Jul; 128(30):1595-6. PubMed ID: 12884147
[No Abstract] [Full Text] [Related]
8. Hypersensitivity and cross-reactivity to cisplatin and analogues.
Shlebak AA; Clark PI; Green JA
Cancer Chemother Pharmacol; 1995; 35(4):349-51. PubMed ID: 7828281
[TBL] [Abstract][Full Text] [Related]
9. Carboplatin-, oxaliplatin-, and cisplatin-specific IgE: cross-reactivity and value in the diagnosis of carboplatin and oxaliplatin allergy.
Caiado J; Venemalm L; Pereira-Santos MC; Costa L; Barbosa MP; Castells M
J Allergy Clin Immunol Pract; 2013; 1(5):494-500. PubMed ID: 24565621
[TBL] [Abstract][Full Text] [Related]
10. Analysis of patients with epithelial ovarian cancer or fallopian tube carcinoma retreated with cisplatin after the development of a carboplatin allergy.
Dizon DS; Sabbatini PJ; Aghajanian C; Hensley ML; Spriggs DR
Gynecol Oncol; 2002 Mar; 84(3):378-82. PubMed ID: 11855873
[TBL] [Abstract][Full Text] [Related]
11. Platinum Chemotherapy Hypersensitivity: Prevalence and Management.
Otani IM; Wong J; Banerji A
Immunol Allergy Clin North Am; 2017 Nov; 37(4):663-677. PubMed ID: 28965633
[TBL] [Abstract][Full Text] [Related]
12. [Successful desensitization using cisplatin after carboplatin-associated hypersensitivity reactions in 3 cases with recurrent ovarian carcinoma].
Hosaka M; Ebina Y; Moriwaki M; Hara Y; Araki N; Todo Y; Takeda M; Watari H; Sakuragi N
Gan To Kagaku Ryoho; 2007 Sep; 34(9):1505-8. PubMed ID: 17876157
[TBL] [Abstract][Full Text] [Related]
13. Risk stratification for desensitization of patients with carboplatin hypersensitivity: clinical presentation and management.
Hesterberg PE; Banerji A; Oren E; Penson RT; Krasner CN; Seiden MV; Wong JT
J Allergy Clin Immunol; 2009 Jun; 123(6):1262-7.e1. PubMed ID: 19501233
[TBL] [Abstract][Full Text] [Related]
14. Low Cross-Reactivity Between Cisplatin and Other Platinum Salts.
Pasteur J; Favier L; Pernot C; Guerriaud M; Bernigaud C; Lepage C; Jouve JL; Isambert N; Collet E
J Allergy Clin Immunol Pract; 2019; 7(6):1894-1900. PubMed ID: 30776524
[TBL] [Abstract][Full Text] [Related]
15. [About side effects of platinum drugs].
Waszkiewicz K
Postepy Hig Med Dosw; 2001; 55(3):387-406. PubMed ID: 11505639
[TBL] [Abstract][Full Text] [Related]
16. Use of cisplatin without desensitization after carboplatin hypersensitivity reaction in epithelial ovarian and primary peritoneal cancer.
Callahan MB; Lachance JA; Stone RL; Kelsey J; Rice LW; Jazaeri AA
Am J Obstet Gynecol; 2007 Aug; 197(2):199.e1-4; discussion 199.e4-5. PubMed ID: 17689649
[TBL] [Abstract][Full Text] [Related]
17. Platinum compounds and therapy related acute promyelocytic leukemia.
Martin J; Majumdar G
Hematol J; 2002; 3(6):321-3. PubMed ID: 12522457
[TBL] [Abstract][Full Text] [Related]
18. Retrospective study of hypersensitivity reactions to chemotherapeutic agents in a thoracic oncology service.
Capelle H; Tummino C; Greillier L; Gouitaa M; Birnbaum J; Ausias N; Barlesi F; Montana M
J Clin Pharm Ther; 2018 Jun; 43(3):320-326. PubMed ID: 29092096
[TBL] [Abstract][Full Text] [Related]
19. Hypersensitivity reactions associated with platinum-containing antineoplastic agents for thoracic malignancies.
Tamiya M; Kuhara H; Hirashima T; Kondo Y; Santo M; Morishita N; Suzuki H; Sasada S; Okamoto N; Kobayashi M; Kawase I
Anticancer Res; 2011 Dec; 31(12):4525-8. PubMed ID: 22199326
[TBL] [Abstract][Full Text] [Related]
20. Carboplatin desensitization.
Keat K; Harnett P; Fulcher DA
Ann Allergy Asthma Immunol; 2007 Nov; 99(5):468-9. PubMed ID: 18051220
[No Abstract] [Full Text] [Related]
[Next] [New Search]
